SAN DIEGO, Oct. 12, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced today that management will
Investors, analysts, and the general public are
Orexigen Investor Contact:Jason Keyes, Chief Financial Officer+1-858- [email protected]
Orexigen Media Contact:Erika HackmannY&[email protected]
View original content:http://www.prnewswire.com/news-releases/orexigen-therapeutics-to-provide-business-update-at-the-2017-bio-investor-forum-300536244.html
SOURCE Orexigen Therapeutics, Inc.
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All